SPONSORS
Elite Sponsors
Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc. is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, is available in the United States. The PDUFA goal date for Aerie’s second product Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a fixed-dose combination of Rhopressa® and latanoprost, is March 14, 2019. Aerie is expanding globally and developing additional product candidates in ophthalmology, including for wet AMD and DME.
Alcon
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.
Bayer Pharma AG
As a leader in ophthalmology, Bayer is committed to delivering science for a better life by addressing unmet needs through scientific progress and innovation. Bayer has established strong internal R&D capabilities in ophthalmology with the aim to bring new therapies to patients suffering from vision impairment and sight-threatening diseases.
Carl Zeiss Medical Technologies
Carl Zeiss Meditec, a world-leading medical technology company, supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete solutions for diagnosis and treatment of eye diseases, innovative visualization solutions for microsurgery, and promising, future-oriented technologies such as intraoperative radiotherapy.
Johnson & Johnson Vision
Johnson & Johnson Vision is committed to improving and restoring sight for patients worldwide. Through their world-leading ACUVUE® Brand Contact Lenses portfolio, newly acquired cataract surgery, laser refractive surgery (LASIK) and consumer eye health businesses, they now serve more than 60 million patients a day across 103 countries. Dual headquartered in Jacksonville, Florida, and Santa Ana, California, Johnson & Johnson Vision has more than 8,400 employees worldwide.
Santen
As a global specialty company dedicated exclusively to ophthalmology, Santen specializes in the research, development and commercialization of pharmaceutical, surgical, and OTC eye care products. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in nearly 70 markets. As a leading company in the field of ophthalmology, Santen aims to contribute to society by providing innovative solutions that address unmet medical needs in glaucoma, retina, uveitis, dry eye, ocular allergy, and refractive disorders.
Premier Sponsor
Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions.
Major Sponsors
Allergan
Allergan (NYSE: AGN) is a unique, global pharmaceutical company focused on developing, manufacturing and commercializing high quality generic and innovative branded pharmaceutical products for patients around the world. The Company has approximately 30,000 employees worldwide and maintains global headquarters in Dublin, Ireland.
Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 3 FDA-approved sustained-release treatments in ophthalmology. In addition, DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018.
Genentech
Founded 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
GenSight Biologics
GenSight Biologics is a clinical-stage biopharma company focused on developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight pipeline leverages two core technology platforms, Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight lead product candidate, GS010, is in PhaseIII trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease leading to irreversible blindness in teens and young adults. GenSight product candidates are designed to be administered in single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Novartis
Novartis is a leading ophthalmology company, with therapies that treat both front and back of the eye disorders, including retina diseases, glaucoma, dry eye and other external eye diseases. In 2016, approximately 200 million patients worldwide were treated with Novartis ophthalmic products.
Ophthotech
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat ophthalmic diseases, with a focus on orphan and age-related retinal diseases.
Opthea Limited
Opthea (ASX:OPT) is developing OPT-302, a VEGF-C/D inhibitor for neovascular AMD and DME. VEGF-C/D promote vessel growth and leakage and may contribute to sub-responsiveness to VEGF-A inhibitors. Opthea has reported outcomes from a Phase 1/2a trial in nAMD (n=51) that evaluated safety and clinical activity of OPT-302 as a monotherapy and in combination with ranibizumab in treatment-naïve and prior-treated patients. OPT-302 was well tolerated and data suggest biological activity with improvements in visual acuity and retinal swelling, suggesting additional clinical benefit with dual targeting of VEGF-A and VEGF-C/D. Opthea is currently recruiting patients in two randomised, controlled studies, including a Phase 2b trial of OPT-302 in combination with ranibizumab for nAMD and a Phase 1b/2a trial of OPT-302 in combination with aflibercept for persistent DME.
Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. Headquartered in Leuven, Belgium, Oxurion is listed on the Euronext Brussels exchange under the symbol OXUR. In the US, Oxurion NV operates ThromboGenics inc. as a subsidiary company.
Piper Jaffray
Piper Jaffray (NYSE: PJC) is a leading investment bank focused on mergers and acquisitions, public offerings, public finance, institutional brokerage, investment management and research. Founded in 1895, the firm is headquartered in Minneapolis with offices across the U.S. and in London, Aberdeen, Zurich and Hong Kong.
Regeneron
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.
Sun Pharmaceutical Industries
Sun Ophthalmics is reenergizing eye care. We are a US division of Sun Pharma, a global specialty pharmaceutical corporation with operations in over 150 countries. We focus on your needs as a professional, offering support so you can focus on your patients. Discover a brighter future in eye care.
Trefoil Therapeutics
Trefoil Therapeutics is developing engineered FGF-1 compounds to treat corneal endothelial dystrophies. The lead compound is unique in addressing multiple unmet needs in corneal disease by mimicking natural biologic processes. The compound is protected by a broad patent portfolio.
The first indication is an intracameral injection for the treatment of Fuchs Dystrophy. Also in development is a topical formulation of TTHX1114 that will treat a number of ulcerative conditions on the front of the cornea.
Trefoil has completed a pre-IND meeting and is preparing an IND for submission in H2, 2019. for the front of the cornea indication. The company completed a Series 1 financing in 2016, led by Hatteras Venture Partners.
The therapeutic categories under development offer an efficient and quick development pathway.
Supporting Sponsors
Aura Biosciences
At Aura Biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed. Our first product candidate, AU-011, is a proprietary viral-like particle bioconjugate that is being developed for the treatment of choroidal melanoma. This cancer is the most common intraocular cancer in adults, is life threatening and there are currently no FDA approved therapies. Aura is developing the first targeted therapy that may enable early treatment intervention with vision preservation to dramatically change the outcomes for patients with this rare and life threatening disease.
Clearside Biomedical
Clearside Biomedical, Inc., is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary SCS™ microinjector to reach diseased tissue through the suprachoroidal space. Clearside’s portfolio of clinical/pre-clinical programs for back-of-the-eye diseases include RVO, uveitis, wet AMD and DME.
Innovation Sponsors
AcuFocus
AcuFocus, Inc., is a privately held ophthalmic medical device company that develops and markets breakthrough technologies for the improvement of vision. Our proven, proprietary technology platform uses a small aperture - or pinhole - effect to allow focused light rays to reach the retina and bring objects into focus. The result is unique, reliable and long-term. Designed specifically for patients with cataracts, the IC-8 IOL combines small aperture optics with the reliability of a monofocal IOL to provide an uninterrupted extended depth of focus. The lens received its CE mark in 2014 and is available in select markets across Europe and Asia. Founded in 2001, AcuFocus is based in Irvine, Calif. For additional information about the IC-8 intraocular lens, visit www.acufocus.com.
Aerpio Pharmaceuticals
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. Our lead product candidate, AKB-9778, is a small molecule Tie2 activator currently in a Phase 2b study (TIME-2b) for the treatment of non-proliferative diabetic retinopathy (NPDR). We are also developing a topical ocular formulation of AKB-9778 for development in primary open angle glaucoma.
Alimera Sciences
Alimera Sciences specializes in the research, development and commercialization of ophthalmic pharmaceuticals. Our commitment to retina specialists and their patients is manifest in our product and development portfolio designed to treat retina diseases. Our sustained release product, ILUVIEN, for the treatment of DME was launched in 2014.
Allegro Ophthalmics
Allegro Ophthalmics is establishing integrin peptide therapy as the next-generation pharmaceutical category for the treatment of vitreoretinal diseases. Currently in multiple Phase 2 studies, Allegro’s Luminate has the potential to provide new treatment options for patients with diabetic macular edema, non-proliferative diabetic retinopathy, neovascular age-related macular degeneration and vitreomacular traction.
ArcScan
ArcScan’s Swept Beam Liquid Interface TM technology delivers dramatic developments in ultrasound imaging not seen in decades. It provides OCT like images of the entire anterior segment from the cornea to the posterior of the lens with patient seat times of just a few minutes, measurement precision on par with optical imaging systems and with the added benefit of making those measurements behind the iris. This is not a handheld device and utilizes many of the components of modern optical imaging systems but using very high frequency ultrasound. Clinical benefits include precision imaging behind the iris for better ICL/IOL sizing, comprehensive anterior segment measurement tracking for early glaucoma management and MIGS evaluation, and wide angle cornea layer mapping for keratoconus screening and inlay evaluations.
Avedro
Avedro is a privately held pharmaceutical and medical device company advancing the science and technology of corneal cross-linking and refractive correction.
Bio-Tissue
Bio-Tissue® is an industry leader in regenerative medicine. From inception, we have focused on introducing game-changing technology to advance standards of care in ocular surface therapy. We recognize and respect the sophistication of the ocular surface, which is why we remain dedicated to understanding its biology.
CorneaGen
CorneaGen is a mission-driven company, committed to transforming how ophthalmologists treat and care for the cornea. As the world's first cornea-focused company, CorneaGen is leading the way for new medical devices, biologics, therapeutics, and interventions for the treatment of the cornea.
Ellex
Ellex works with leading physicians, technical institutions and universities to discover, develop and deliver new ways to treat of some of the world’s most prevalent eye conditions. Initially with SLT Selective Light Therapy, then through our 2RT® Retinal Rejuvenation Therapy, and more recently with the introduction of iTrack™ — our solution for minimally invasive glaucoma surgery (MIGS) — we’re expanding our focus on the development of restorative, rejuvenative treatment options that work holistically with the body’s natural healing ability.
Eyenovia
Eyenovia is a late-stage ophthalmic biopharmaceutical company with a lead program for the prevention of myopia (nearsightedness) progression. Progressive myopia is a serious, site-threatening condition that may impact up to 5 million children in the United States, with similar numbers for Europe and many more in Asia. Through the use of our transformative ophthalmic delivery platform, Eyenovia is preparing a single, de-risked Phase 3 study of MicroPineTM that may lead to the first FDA-approved treatment for this condition.
Eyenovia makes new therapies possible. Our unique delivery platform uses breakthrough piezo-print technology for high-precision micro-dosing. Micro-dosing allows for fully effective therapies that may also avoid many tolerability and side-effect issues associated with traditional eye drop delivery.
Eyevance
Eyevance Pharmaceuticals is a Fort Worth, Texas based ophthalmic pharmaceutical company committed to advancing ocular health by developing and commercializing innovative and impactful products that enable optimal vision and better quality of life for all patients. Eyevance has established a portfolio of market-ready products and a pipeline of unique assets that address significant unmet needs, including rare diseases and orphan conditions, while also focusing on products with a legacy of proven safety and efficacy.
Gemini Therapeutics
Gemini Therapeutics is a biotechnology company focused on redefining dry AMD through the development of a series of first-in-class precision therapeutics. Each one of our therapeutic candidates is designed to directly compensate for the effect of a molecular abnormality found in patients with an unusually high risk genetic profile. Our disease-focused engine uses the process of translating precision therapeutics with unprecedented genotypic and phenotypic data as a method of drug discovery. We currently have 3 programs in preclinical development and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. We are funded by leading life science investors and powered by academic partnerships around the world.
Graybug Vision
Graybug Vision is developing novel products for the treatment of people with ocular diseases. The company’s lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. Graybug Vision has developed a library of compounds to treat glaucoma per year into the subconjunctiva.
iStar Medical
iSTAR Medical is a clinical-stage company focused on the development of novel ophthalmic implants for glaucoma. It has exclusive rights to a novel porous material called STAR(r) which exhibits outstanding anti-fibrotic properties therefore providing the foundation for the development of a new class of MIGS devices.
Kala Pharmaceuticals
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYSTM (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
LacriScience
With our sensors, furnished with an abundance of chemistries, we can accurately identify and quantify a whole suite of ophthalmic disorders such as inflammation(MMP-9), Adenovirus,Tryptase, etc. Discuss bench and clinical data using the advanced stage of development of LacriPen, positioning it as the most versatile diagnostic technology SPR, in the industry.
Lagunita Biosciences
Lagunita Biosciences is a healthcare investment company and incubator that creates and grows early stage companies to commercialize impactful translational science that addresses significant clinical needs. We evaluate opportunities in five key areas that correspond to the strengths and expertise of our team and network: Ophthalmology, protein engineering & drug discovery, surgical devices, optical diagnostics and therapeutics and mobile health.
LumiThera
LumiThera, Inc. is a medical device company focused on treating patients with degenerative eye diseases. The company has significant expertise in the use of photobiomodulation (PBM), for acute and chronic ocular diseases and disorders. LumiThera’s first product, the award winning Valeda™ Light Delivery System, is currently CE Marked in the European Union for the treatment of dry AMD and is in clinical trials.
Mati Therapeutics
Mati is developing the Evolute platform - a non-invasive sustained drug delivery platform using punctal plugs as a delivery device. Products using the Evolute system are being developed for glaucoma, dry eye, allergy and inflammation. In prior studies, the Stable Fit punctal plug design has shown retention rates of 92% and 96% over a 12 week follow up period. Mati is currently conducting a Phase II trial of nepafenac in patients undergoing cataract surgery and positive interim results were announced in September. Mati will soon be undertaking a study using travoprost in patients with glaucoma and ocular hypertension and further plans to develop a steroid for post-cataract inflammation. This technology platform is well-supported with 114 patents issued in major countries around the world.
MC2 Therapeutics
MC2 Therapeutics is a privately held late clinical stage emerging dermatology and eye care company. Using its proprietary new vehicle PAD™ Technology MC2 Therapeutics is developing a pipeline of new topical drugs with unique clinical profiles designed for optimal patient compliance. Lead projects include MC2-01 Cream for psoriasis (US Ph3), MC2-03 Eye Drop for dry eye (pivotal Ph2) and MC2-02 Cream for uremic pruritus (launch expected in 2019).
Mynosys Cellular Devices
Mynosys Cellular Devices Inc. is a medical device company providing innovative solutions to help surgeons achieve perfection in cataract surgery. Our product Zepto®, is a unique micro-fabricated instrument that provides unmatched precision during surgery on a millisecond time scale to tackle routine and challenging cases with confidence and efficiency. Zepto® provides surgeons of all skill levels an inexpensive, easy to use, automated method for producing high quality anterior lens capsulotomies. Zepto® integrates seamlessly into the cataract surgery routine and its unique clinical device characteristics make it an attractive product platform having the unique capability of centering on the patient's visual axis, inter-operatively will significantly improve capsulotomy overlap of the IOL.
Neurolens
Inspired by a breakthrough discovery linking optometry and neurology, neurolenses are the first and only prescription lenses that add a contoured prism to bring the eyes into alignment, relieving stress on the trigeminal nerve. This nerve is the largest and most complex nerve connected to the brain, and when stimulated causes many of the symptoms people experience when using digital devices, reading or doing near work. Ninety-three percent of patients prescribed neurolenses found symptom relief. neurolens is headquartered in Costa Mesa, Calif.
Nicox
Nicox is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. The Company’s strategy is to maximise the potential of its proprietary nitric oxide (NO)-donating research platform and its products and product candidates through in-house development and industry-leading collaborations.
Notal Vision
Notal Vision is an Artificial Intelligence driven, Cloud based company that has created an ecosystem to support the early detection and personalized treatment of vision threatening diseases.
ForeSee Home leverages the ecosystem, seamlessly connecting patients to their eye care professional to monitor and detect the switch of patients from Dry to Wet AMD at the earliest possible stage.
Notal Vision is developing a home based OCT platform to personalize treatment for patients with Wet AMD,DME and RVO.
Novaliq
Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology.
With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of eye patients:
NovaTears® improves the signs and symptoms of dry eye disease (DED) and is marketed under CE-approval in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm.
Two drugs are in the late stage of clinical development with results expected in Q3 2018:
- CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of DED with a demonstrated early onset of action and excellent tolerability, is being evaluated in the pivotal phase 2b/3 ESSENCE trial.
- NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction (MGD), is being evaluated in the phase 2 SEECASE trial.
Headquartered in Heidelberg, Germany, Novaliq has an office in Cambridge, MA, USA. The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.
Omega Ophthalmics
Omega Ophthalmics, LLC is a startup co-founded by serial entrepreneur, Rick Ifland, and ophthalmologist, Gary Wortz, MD, to develop an entirely new class of intraocular lenses with the goals of improving refractive outcomes and future-proofing the eye for the advancements in the future.
Oyster Point Pharma
Oyster Point Pharma is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat ocular surface disease.
PanOptica
PanOptica is enrolling a phase I/II dose-ranging study with once daily topical anti-VEGF treatment in newly diagnosed patients with neovascular (wet) AMD. Data is expected mid-2019. Co-founders Paul Chaney and Dr. Martin Wax lead a small, experienced development team enabled by the support of SV Health Investors and Third Rock Ventures.
PowerVision
PowerVision has developed a fluid-controlled accommodating IOL designed to restore youthful vision. The FluidVision® AIOL provides True Accommodation™ by mimicking the eye’s natural accommodative process to transport fluids inside it, creating true shape change. The Company has shown in clinical trials that it can deliver clear vision at all distances.
ReNeuron
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
Sight Sciences
In 2011, Sight Sciences was founded to change the way the practice of ophthalmology and optometry thinks about and treats the leading causes of eye disease. Supported by leading medical technology and private equity investors, Sight Sciences operates two business lines: surgical and non-surgical systems. Its surgical product portfolio consists of the OMNI™ Surgical System, TRAB®360 and VISCO360® for use by ophthalmologists. Its non-surgical product portfolio consists of its TearCare™ technologies for use by ophthalmologists and optometrists.
SightGlass Vision
SightGlass Vision, Inc., a clinical stage, start-up biotech/medical device company based in Menlo Park, CA. SightGlass is developing innovative spectacle lenses to reduce progression of myopia in children. Based on research at the University of Washington, SightGlass was founded in 2016 by Prof. Jay Neitz and Prof. Maureen Neitz, world-renowned vision researchers, and Dr. Thomas Chalberg, a serial entrepreneur in the biotechnology and medical device sectors. Myopia is rising rapidly around the world, and by 2050, approximately 5 billion people will be myopic. SightGlass's mission is to reduce myopia progression for millions of children suffering from myopia around the world.
Silk Technologies
SightGlass Vision, Inc., a clinical stage, start-up biotech/medical device company based in Menlo Park, CA. SightGlass is developing innovative spectacle lenses to reduce progression of myopia in children. Based on research at the University of Washington, SightGlass was founded in 2016 by Prof. Jay Neitz and Prof. Maureen Neitz, world-renowned vision researchers, and Dr. Thomas Chalberg, a serial entrepreneur in the biotechnology and medical device sectors. Myopia is rising rapidly around the world, and by 2050, approximately 5 billion people will be myopic. SightGlass's mission is to reduce myopia progression for millions of children suffering from myopia around the world.
Tracery Ophthalmics
Tracery is a clinical stage ocular imaging & health tech company that harnesses image-based and non-image-based health data, and Artificial Intelligence for the development of new diagnostic tools for Precision Drug Development, first focusing on Age Related Macular Degeneration (AMD).
Tracery’s platform leverages advanced computing to identify the right person, for the right clinical trial, targeting the right pathway with the right chemistry. We do this by: (1) stratifying novel phenotypes using our proprietary functional imaging method and database, (2) correlating these with the patient’s molecular makeup and health data, and (3) honing potential therapeutics through in silico drug design. By centralizing through the cloud, Tracery aims to provide data, information and answers as a service providing new biomarkers in 2 years rather than 10.
Translatum Medicus Inc
Translatum Medicus inc is a pre-clinical drug development company uniquely focusing on macrophage biology in the treatment of blinding eye disease, first targeting “dry” Age Related Macular Degeneration (AMD) a leading cause of irreversible blindness.
Translatum’s patented lead drug candidate, TMi-018, is a first-in-class transcriptional regulator of macrophage polarization that is dose-dependently efficacious in pre-clinical models of Geographic Atrophy, the end-stage of dry AMD. It has demonstrated stability and suitability for extended delivery, and is safe in non-GLP toxicity studies. With active pharmaceutical ingredient (API) production underway, and a strong leadership team that includes extensive large pharma and startup experience, the company is currently raising Series A funds to move to early phase clinical trial.
Trial Runners
Trial Runners is an ophthalmology CRO providing biotech and pharmaceutical companies with clinical research management services. During the past 9 years, we have worked on over 50 clinical studies researching innovative ways to manage or cure diseases related to the eye.
Founding Sponsors
Clarus
Clarus is a global investment firm dedicated to life sciences. Founded in 2005, our Portfolio includes public and private companies in the biotechnology and healthcare diagnostic sectors. Clarus is presently managing $2.6 billion.
InterWest Partners
For over 37 years InterWest has partnered with entrepreneurs to build award winning healthcare and technology companies. As we complete investing InterWest X, a $650M fund, we continue to believe that providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving company.
Versant Ventures
Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, nearly 50 Versant companies have achieved successful acquisitions or IPOs.
Media Partners
Bryn Mawr Communications
Bryn Mawr Communications’ (BMC) eye care publications are uniquely positioned in ophthalmology to serve both physicians’ and industry’s needs.
Cataract & Refractive Surgery Today, Cataract & Refractive Surgery Today Europe, Glaucoma Today, Retina Today, MillennialEYE, and CollaborativeEYE showcase in-depth coverage of surgical approaches, device development, pharmacologic innovations, industry trends, and practice management.
By partnering with key opinion leaders, BMC’s eye care publications balance institutional wisdom with fresh perspectives through print magazines, an expansive video library, and timely news feeds. BMC’s in-house production team brings information directly to physicians through live meetings, simulcasted symposia, live surgeries, and more.
Ethis
The mission of Ethis, Inc., is to facilitate global innovation in eyecare by providing strategic analysis, exceptional content across a wide range of media, and an extensive network of key ophthalmic and optometric opinion leaders to our industry and academic partners around the world.
EyeNet
EyeNet is the official newsmagazine of the American Academy of Ophthalmology and the premier source among the ophthalmic trade press of credible information for ophthalmologists. EyeNet delivers practical clinical information that can be applied immediately in patient care, plus coverage of a broad range of subjects of interest to ophthalmologists, including business and news —all in a concise, highly readable format. For the 9th year in a row, EyeNet is ranked #1 in High Readers, or the most dedicated readers in the field.
EyeWorld
As the news and feature magazine of the American Society of Cataract & Refractive Surgery, EyeWorld serves as the premier publication for anterior segment surgeons. The magazine provides comprehensive ophthalmic news and the latest clinical information in the areas of cataract, refractive, cornea, glaucoma, and retina. Each article is carefully reviewed by the editorial staff and the article’s sources before publication. EyeWorld Meeting Reporter/Video Reporter is produced live onsite and contains information on the latest cutting-edge technologies and techniques in the ophthalmic industry. The EyeWorld Education Hub is a new way to view content. Simply choose a disease state to view surgical videos, symposia, webinars, clinical interviews, and articles on that topic.
Healio
Healio.com, the online home of Ocular Surgery News, offers daily news updates, online-only content, extensive CME and specialized email News Wires. Download the new Healio.com/Ocular Surgery News App on iTunes- Search “Ocular Surgery News.” As the best-read newspaper for ophthalmologists, Ocular Surgery News holds a unique place among the eye care publications. With the largest dedicated staff focused solely on ophthalmology, OSN strives to bring our readers a deeper understanding of the news and events that affect their profession.
Market Scope
Market Scope is the leading source for market data, independent perspective, and objective analysis in today’s ophthalmic marketplace.
Market Scope surveys ophthalmologists regarding procedure volumes, surgical techniques, and product use. This data, along with an extensive database, wide-ranging knowledge of ophthalmic products and technology, and comprehensive network of industry contacts, is used to create more than 20 specialized, yearly reports on the ophthalmic industry.
These reports are used to measure performance, make investment decisions, and allocate resources and serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return on investment decisions in the industry. Market Scope has been committed to ophthalmology for more than 20 years and continues to be the most highly valued source for accurate and timely information about ophthalmic markets.
Ophthalmology Times
Ophthalmology Times is a physician-driven media brand that presents cutting-edge advancements and analysis from around the world in surgery, drug therapy, technology, and clinical diagnosis to elevate the delivery of progressive eye health from physician to patient. Ophthalmology Times’ vision is to be the leading content resource for ophthalmologists. Through its multifaceted content channels, Ophthalmology Times will assist physicians with the tools and knowledge necessary to provide advanced quality patient care in the global world of medicine.
The Ophthalmologist
Three key characteristics set The Ophthalmologist apart:
First, we tell stories. We’re able to tell some of the greatest stories in ophthalmology – straight from the people leading the work, in order to educate, inform, influence and entertain.
Second, we provide genuine insight. The team gets it. The Editorial team all have an academic biomedical research background, have written the papers and stood at the podium. We speak “doctor”, we “do” research.
Third, we engage with everyone. Insight comes from observation and conversation. We travel the world to meet and hear what ophthalmologists, entrepreneurs, key industry figures and policymakers have to say – and that’s directly reflected in the content.
Retina Specialist
Retina Specialist focuses on the latest advances in the medical management and surgical treatment of diseases of the retina, along with practical, real-world advice from leading clinicians and other experts on the keys to a successful retina practice. The retina specialist value it as a must-read resource from the publishers of Review of Ophthalmology.
Review of Ophthalmology
Review of Ophthalmology is a monthly publication featuring clinically relevant information on surgical technique, new technologies and disease diagnosis and management. Review presents timely articles on ophthalmic subspecialties, such as glaucoma, retina, refractive/cataract surgery, cornea and external disease, pediatric ophthalmology and ocuplastics, as well as current reports on news, regulatory issues, practice management, contact lenses and optical.
touchOPHTHALMOLOGY
touchOPHTHALMOLOGY.com is an independent information resource designed to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity, with open access articles and multimedia content.
The US Ophthalmic Review is a peer-reviewed, open access, bi-annual journal specializing in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting.
Supporting Organizations
GRF
Glaucoma Research Foundation (GRF) is a national nonprofit founded in 1978 in San Francisco to encourage innovative research toward better treatments for people with glaucoma. GRF has funded more than $50 million of grants and projects in 35 years. In addition to advancing innovation in glaucoma research, GRF provides education and support for people with glaucoma and sponsors catalyst meetings like the annual Glaucoma 360 New Horizons Forum to foster collaboration and speed the cure. The Glaucoma Research Foundation mission is to prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.
OWL
Advancing Diversity in Leadership. OWL is a 900+ member professional organization focused on leadership development. Our mission is to promote and develop diverse leadership to advance Ophthalmic Innovation and Patient Care. We hold local "OWL Connect" events, online learning sessions and Signature Events at ASCRS and AAO.